SHERWOOD, Ore., Jan. 7, 2013 /PRNewswire/ -- Entia
Biosciences (OTCBB: ERGO), a food science biotechnology company and
emerging leader in the field of Nutrigenomics, announced today that
it has filed a PCT patent covering the use of Ergothioneine and/or
Vitamin D2 to improve the growth and health of hair, skin and
nails. The scientific knowledge underpinning this application
claims priority to a provisional use patent filed on December 29, 2011 that addresses naturally and
synthetically produced forms of these important nutrients and the
products that contain them.
Research conducted by Entia and others suggests that the rapidly
dividing stem cells of the hair, skin, and nails are particularly
sensitive to damage and oxidative stress from free radicals, the
unstable molecules that the body produces when it metabolizes food
into energy. Free radicals are unstable because they have an
uneven number of electrons and try to bind with normal molecules to
steal an electron in a process called oxidation, which uncontrolled
can lead to a chain reaction producing more and more free radicals
and inflammation that can seriously impair the health and
rejuvenation of cells, the immune system, and the expression of our
DNA. Oxidation and/or oxidative stress accelerates the
processes of aging, such as the breakdown of collagen in skin and
the premature loss and discoloration of hair.
Our bodies try to protect us from this damage by producing
enzymes (glutathione peroxidase, superoxide dismutase, reductase,
and catalase) that help to control the free radicals created from
our normal body processes. However, they are not capable of
handling this function without the help of antioxidants, the
protective molecules from our diet that bind to unstable free
radicals and neutralize them by providing an electron.
Ergothioneine and Vitamin D2 are two of the most powerful
antioxidants in nature and the disclosed invention describes how
their ingestion and/or topical application can delay and reverse
the damaging effects of oxidation in the hair, skin, and
nails. The Nation of Canada
recently published a Notice of Allowance for Entia's use of
Ergothioneine and its genetic transporter (SLC22A4) in the
treatment of a wide variety of inflammatory diseases, including
diabetes, Alopecia and psoriasis, and other Ergothioneine and
Vitamin D2 patents have been issued or are pending in N. America,
Europe, and Asia.
"Beautiful and vibrant hair, skin and nails are the most obvious
outward indications of a person's health and vitality," says
Marvin S. Hausman MD, Chairman and
Chief Executive Officer of Entia Biosciences. "Changes in their
appearance can be devastating in our society, signaling the loss of
our youth and the fear that something more serious may be occurring
within our bodies. Entia is aware that the complex anatomy of skin,
hair and nails represents a dynamic cellular system that requires a
combination of targeted nutrition from the inside as well as the
outside. The new knowledge of nutritional regulation contained
within this patent is critical for the development of effective
anti-aging strategies and the prevention and treatment of diseases
afflicting millions of people around the world."
Rapidly dividing cells, especially in the skin, hair and nails
that are directly exposed to environmental hazards such as
ultraviolet radiation, locally applied chemicals and toxins, are
systems that are particularly sensitive to oxidative stress and
free radical damage. This sensitivity can be seen in the many
women that experience hair loss during and after pregnancy, as well
as hair loss and premature graying associated with emotional
stress, hormonal imbalance, thyroid imbalance and nutritional
deficiencies. Entia's proprietary ErgoD2® formulations are
designed to deliver the vital nutrients needed for healthy stem
cell function, which is critical to the anti-aging process.
About Entia Biosciences
Entia is an authority on the clinical effects of oxidative
stress and free radical reactions and is bringing this expertise to
food science biotechnology and the field of nutrigenomics.
The Company identifies, scientifically validates, patents, and
commercializes solutions that address multi-billion dollar markets
for health, beauty and agriculture.
Any statements contained in this press release that relate to
future plans, events or performance are forward-looking statements
that involve risks and uncertainties including, but not limited to,
the risks associated with the transaction described in this press
release, and other risks identified in the filings by Entia
Biosciences with the Securities and Exchange Commission. Further
information on risks faced by the Company and its shareholders are
detailed in the Form 10-K for the year ended December 31, 2011 and in its subsequent Quarterly
Reports on Form 10-Q. These filings are or will become available on
a website maintained by the Securities and Exchange Commission at
http://www.sec.gov. The information contained in this press release
is accurate as of the date indicated. Actual results, events or
performance may differ materially. Entia does not undertake
any obligation to publicly release the result of any revision to
these forward-looking statements that may be made to reflect events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
For more information, please visit our web sites at
www.entiabio.com or contact:
Devin Andres
Vice President
Entia Biosciences, Inc.
13565 SW Tualatin-Sherwood Rd Sherwood,
OR, 97140
Phone: (503) 334-3575 Email: info@entiabio.com
SOURCE Entia Biosciences